Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and…
Becton Dickinson ($BDX) gradually starting to show some strength (and that goes for many Med-tech) following lengthy underperformance @IBDinvestors @marketsurge Most aren't talking about Healthcare's push to highest levels since Aug today (Both XLV, RSPH) & some encouraging…
14 analysts rate BDX Buy on consensus.
Consensus price target: $195.57 (-1.58% downside from $198.71)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Feld Michael EVP, Chief Revenue Officer | Sep 28, 2026 | Sale | 76 | $13.96K |
| Feld Michael EVP, Chief Revenue Officer | Aug 26, 2026 | Sale | 165 | $31.1K |
| Polen Thomas E Jr director, Chairman, CEO and President | Aug 13, 2026 | Sale | 4,152 | $768.12K |
| Goette Roland EVP and President, EMEA | Aug 11, 2026 | Sale | 2,438 | $440.89K |
| Feld Michael EVP, Chief Revenue Officer | Jul 27, 2026 | Sale | 75 | $11.78K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $21.84B | +8.23% | $1.68B |
| 2024 | $20.18B | +4.16% | $1.71B |
| 2023 | $19.37B | +2.66% | $1.48B |
Stock data for BDX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics